Disease progression endpoints offer more granular insight into cardiovascular disease than mortality and major adverse cardiac events.

“So the benefit of this is you kind of get to you still get a a harder endpoint than just biomarkers, but you can you can get a little bit more granular than just looking at some of like kind of a I guess the way to describe mortality and cardiovascular disease events is big blunt instruments.”